Navigation Links
IDM Pharma Announces Phase 3 Mifamurtide (L-MTP-PE) Study Demonstrating Improved Survival Published in the Journal of Clinical Oncology
Date:2/4/2008

cturing and controls (CMC) items, in a satisfactory manner during the extension provided by the CHMP, whether the final opinion of the CHMP will be consistent with the non-binding opinion of the CHMP, whether the European Commission will follow the final opinion of the CHMP once issued, whether the likely timing for the final opinion of the CHMP and the regulatory decision in Europe will occur as expected by the Company, the possibility that the Company may not be able to collect, analyze and submit additional data in an amendment to the NDA for L-MTP-PE within the timeframe expected by the Company, if at all, the possibility that such data will not support the benefit of L-MTP-PE in the treatment of non-metastatic osteosarcoma, will not allow a more robust analysis of L-MTP-PE, will not continue to support its overall survival benefit in osteosarcoma, and may not provide substantial evidence for the potential regulatory approval of L-MTP-PE, the timing of the FDA's and EMEA's review of the submissions for marketing approval of L-MTP-PE, the ability of the Company to respond to questions raised by the FDA and EMEA in a satisfactory manner, the time needed to respond to any issues raised by the FDA and EMEA with regard to regulatory submissions for L-MTP-PE, the possibility that regulatory authorities may not consider preclinical and early clinical development work conducted by Ciba-Geigy and efficacy data from the Phase 3 trial conducted by Children's Oncology Group as adequate for their assessment of L-MTP-PE, which may cause delays in review, may result in the regulatory authorities requiring the Company to conduct additional clinical trials, or may result in a determination by the regulatory authorities that the data does not support marketing approval, whether regulatory authorities will approve L-MTP-PE within the time frame expected by the Company or at all, and whether the Company will be able to manufacture and commercialize L-MTP-PE even if it is approved b
'/>"/>
SOURCE IDM Pharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
9. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... , May 22, 2015  RegeneRx Biopharmaceuticals, Inc. ... a peer-reviewed publication of the results of the ... (RegeneRx,s preservative-free eye drops) for the treatment of ... environment (CAE ® ) model.  The exploratory study ... which were previously disseminated by the Company in ...
(Date:5/22/2015)... 22, 2015   InspireMD, Inc. (NYSE MKT: NSPR) ... systems ("EPS"), today announced that its CGuard TM Embolic ... investigator Prof. Piotr Musialek , at the EuroPCR ... France . PARADIGM, an investigator-initiated P ... A roti D revascularization I n symptomatic and ...
(Date:5/22/2015)... , May 22, 2015 ... clinical research unit with a worldwide reputation for ... its frequent publications in peer reviewed medical journals. ... stakeholders and regulators in discussions about rules for ...      (Logo: http://photos.prnewswire.com/prnh/20150522/745125) , Clinical ...
Breaking Medicine Technology:Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 2Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 3Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 4InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 2InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 3InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 4
(Date:5/23/2015)... CA (PRWEB) May 23, 2015 Add High-Quality ... from Pixel Film Studios. , It's as simple as dragging ... utilizing the included tool for full effect. , Including ... on high-dynamic range 5k sensors making this the ultimate bundle ... prismatic flares included in this package are movie files designed ...
(Date:5/22/2015)... (PRWEB) May 22, 2015 The ... communication and capacity are intersecting to create new ... society, the opening speaker at WesternU's 34th annual ... Lieut. Gov. Gavin Newsom, a former San Francisco ... keynote speaker at the graduation ceremony for WesternU's ...
(Date:5/22/2015)... San Francisco, CA (PRWEB) May 22, 2015 ... is hosting two exciting events in June. They will ... First Professional Doctorate and a two-day class on Classical ... 1:30-2:30 p.m. June 3, Dr. Steve Given, the Dean ... he will discuss the new First Professional Doctorate program. ...
(Date:5/22/2015)... Liverpool, OH (PRWEB) May 22, 2015 ... announced that Kyle Johnson, the health system’s Chief Financial ... other interests. Johnson has served as the company CFO ... Wesley West will be joining the health system as ... on an interim basis, while the Board of Trustees ...
(Date:5/22/2015)... May 22, 2015 Following yesterday’s announcement ... agreement with US-based health brand Nature’s Way, Marc St-Onge ... Retention of Ascenta Skin is an integral part of ... about this opportunity to further develop Ascenta Skin into ... Ascenta Skin is a breakthrough, anti-aging skincare supplement featuring ...
Breaking Medicine News(10 mins):Health News:Developers at Pixel Film Studios Release ProFlare 5K Prism for Final Cut Pro X. 2Health News:Newsom to WesternU Grads: The Future is Inside You 2Health News:Newsom to WesternU Grads: The Future is Inside You 3Health News:ACTCM Announces Upcoming June Events 2Health News:River Valley Health Partners Announces CFO Transition, Appointment of Interim CFO 2Health News:Ascenta Skin President Announces Plans to Grow Brand 2
... Treating patients who have chronic hepatitis C and advanced ... liver enzymes, viral levels and liver inflammation, but the ... serious liver disease, a study finds. , These findings ... Treatment Against Cirrhosis (HALT-C) and are reported in the ...
... Mitigating Outbreaks of Vector-Borne Disease Utilizing Satellite Remote Sensing ... Dec. 10, 2008 8 - 9:45 a.m. , ... Hygiene Annual Meeting, Sheraton New Orleans , This ... and potentially halt vector-borne disease outbreaks using remote sensing ...
... Overall medical and pharmacy costs in,people with diabetes can ... in,individuals receiving regular, non-surgical periodontal services, according to,a recent ... showed the same,procedures were linked to as much as ... underscore the importance of the link,between medical and dental ...
... from LifeMasters Supported SelfCare, Inc. shows that physicians who receive our ... status of their patients, responded quickly to the results with treatment ... ... Irvine, Calif. (Vocus) December 9, 2009-- New research ...
... YORK, Dec. 9 The United Spinal Association ( www.UnitedSpinal.org ... City metropolitan area to call 311 to request ... , This system links passengers ... Residents and visitors to NYC can call 311 for a ...
... SAN FRANCISCO, Dec. 9 Quantros, a leading ... healthcare industry, and the,Institute for Safe Medication Practices ... science in medication error prevention. ISMP will,work ... identify opportunities,to guide medication-centric intervention and best practices. ...
Cached Medicine News:Health News:Hepatitis C treatment reduces the virus but liver damage continues 2Health News:Hepatitis C treatment reduces the virus but liver damage continues 3Health News:University of Michigan, Blue Care Network Study Quantifies Health Care Savings of Regular Dental Care for Patients with Diabetes 2Health News:Research Shows Successful Physician Engagement in LifeMasters Disease Management Programs 2Health News:Research Shows Successful Physician Engagement in LifeMasters Disease Management Programs 3Health News:Accessible Dispatch Program: Accessible Taxi Service for Wheelchair Users in New York City 2Health News:Quantros and ISMP Announce Collaboration Agreement to Further Medication Safety 2Health News:Quantros and ISMP Announce Collaboration Agreement to Further Medication Safety 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: